Opportunity cost of antidepressant prescribing in England: analysis of routine data

Sandra Hollinghurst, David Kessler, Tim J Peters and David Gunnell

BMJ 2005;330;999-1000; originally published online 18 Mar 2005; doi:10.1136/bmj.38377.715799.F7

Updated information and services can be found at:
http://bmj.com/cgi/content/full/330/7498/999

These include:

References
This article cites 2 articles, 1 of which can be accessed free at:
http://bmj.com/cgi/content/full/330/7498/999#BIBL
1 online articles that cite this article can be accessed at:
http://bmj.com/cgi/content/full/330/7498/999#otherarticles

Rapid responses
5 rapid responses have been posted to this article, which you can access for free at:
http://bmj.com/cgi/content/full/330/7498/999#responses
You can respond to this article at:
http://bmj.com/cgi/eletter-submit/330/7498/999

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

- Mood disorders (including depression) (555 articles)
- Drugs: psychiatry (326 articles)
- Psychology (336 articles)

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to BMJ go to:
http://bmj.bmjjournals.com/subscriptions/subscribe.shtml
Opportunity cost of antidepressant prescribing in England: analysis of routine data

Sandra Hollinghurst, David Kessler, Tim J Peters, David Gunnell

Recently, prescribing of antidepressant drugs has increased exceptionally. At the same time, concerns have been raised about the medicalisation of human distress and, more recently, about the safety of antidepressants.1

Many general practitioners would like to refer patients for psychological treatment, for which there is good evidence of effectiveness, but are constrained by the lack of NHS therapists. We estimated the opportunity cost of the recent rise in antidepressant prescribing by valuing it in terms of an effective alternative treatment—cognitive behaviour therapy.

Methods and results

We used Department of Health data on the number and cost of antidepressant drugs dispensed in the community in England to quantify the changes between 1991 and 2002. The baseline year (1991) was chosen to ensure a meaningful timescale and to cover a period of consistent approaches to recording. We took population statistics from www.statistics.gov.uk/statbase, and applied an inflation rate of 32% (from 1991-2002).

We estimated the number of patients that could have been treated using cognitive behaviour therapy in 2002, had the rise in prescribing not occurred and the associated costs been diverted to psychological treatment and therapists. We costed the time of a clinical psychologist, including supervision (total equivalent £40 168 ($74 883; 657 738) full time a year).2

We estimated that each therapist could treat six patients a day for 40 weeks a year and that a treatment episode for mild or moderate depression would comprise six sessions.3 We did a limited sensitivity analysis assuming that graduate mental health workers (£25 475 a year) rather than psychologists provided treatment and that treatment episodes consisted of 18 sessions in line with the National Institute for Clinical Excellence’s recommendation for moderate or severe depression.4

Between 1991 and 2002, prescriptions per head for all antidepressants increased 2.8-fold and the total cost (adjusted for inflation) increased by £310m; the increase was almost entirely due to selective serotonin reuptake inhibitors (figure). These costs could have been raised about the medicalisation of human distress and, more recently, about the safety of antidepressants.1


11 Duke T, Micheal A, Mokela D, Wal T, Reeder J. Chloramphenicol or ceftriaxone, or both, as treatment for meningitis in developing countries. Arch Dis Child 2005;90:536-9. (Accepted 22 February 2005)

doi 10.1136/bmj.38408.471991.8F

This article was posted on bmj.com on 18 March 2005: http://bmj.com/cgi/doi/10.1136/bmj.38377.715799.F7


11 Duke T, Micheal A, Mokela D, Wal T, Reeder J. Chloramphenicol or ceftriaxone, or both, as treatment for meningitis in developing countries. Arch Dis Child 2005;90:536-9. (Accepted 22 February 2005)

doi 10.1136/bmj.38408.471991.8F

This article was posted on bmj.com on 18 March 2005: http://bmj.com/cgi/doi/10.1136/bmj.38377.715799.F7
Comment

Resources associated with higher levels of NHS antidepressant prescribing in England in 2002 compared with 1991 could have been used to deliver cognitive behaviour therapy to 1.54 million patients, more than a third of adults with depression or mixed anxiety depression. The recent rise in antidepressant prescribing is likely to be due to increased awareness of depression by patients and professionals; reduced side effects associated with newer antidepressants; and the broadening range of indications for which antidepressants are prescribed (for example, panic disorder, seasonal affective disorder, premenstrual syndrome). Despite concern about the dangers of antidepressants, evidence of ineffective and inefficient prescribing, and the effectiveness of alternative treatments, drugs are overwhelmingly the mainstay of treatment for depression in general practice. Increases in the pharmacological treatment of depression have not been matched by the development of psychological services of proved effectiveness, which may reflect the absence of a powerful body, equivalent to the pharmaceutical industry, to promote their development and use.

Although cognitive behaviour therapy is relatively expensive and its population cost effectiveness has not been shown, other cheaper alternatives to both antidepressants and psychotherapy—for example, self-help and exercise—may be of equal benefit to patients with mild to moderate depression. Our analysis takes no account of the training costs of psychotherapists but we have also ignored the cumulative cost of drugs incurred in the 11 years. Despite these limitations, the analysis highlights the scale of resources expended in this area and the uncertainty around alternative treatment for particular groups of patients; the results indicate that there is a clear need for further research to establish the most appropriate balance between drugs and non-pharmacological treatments for depression.

We thank Steve Pilling and Glyn Lewis for helpful comments and suggestions about an earlier draft of this paper.

Competing interests: DG had the idea. SH did the analysis and drafted the paper. All authors contributed to the interpretation of the results and the editing of the paper. SH and DG are guarantors.

Funding: None.

Ethical approval: Not needed.

(Accepted 10 January 2005)

doi 10.1136/bmj.38377.715799.F7

What is already known on this topic

The prescribing of antidepressant drugs has risen substantially in the United Kingdom since the early 1990s.

Cognitive behaviour therapy is an effective alternative to antidepressant drugs

What this study adds

Opportunity costs indicate that development of psychological therapies is a feasible alternative to antidepressants

What this study adds

Opportunity costs indicate that development of psychological therapies is a feasible alternative to antidepressants.